Last reviewed · How we verify

Benzocaine Otic Solution

Lachlan Pharma Holdings · Phase 3 active Small molecule ✓ Verified May 2026

Benzocaine Otic Solution is a Local anesthetic Small molecule drug developed by Lachlan Pharma Holdings. It is currently in Phase 3 development for Otalgia (ear pain) / acute otitis media pain relief.

Benzocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission in the ear.

Benzocaine Otic Solution is a small molecule topical anesthetic used to treat pain. It is indicated for the treatment of acute otitis media in children, as shown in a Phase III clinical trial (NCT03116737).

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameBenzocaine Otic Solution
SponsorLachlan Pharma Holdings
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaOtology / Pain Management
PhasePhase 3

Mechanism of action

Benzocaine works by inhibiting sodium influx through nerve cell membranes, which stabilizes the neuronal membrane and prevents the initiation and conduction of nerve impulses. When applied topically to the ear canal, it rapidly numbs the affected tissue, providing local anesthetic relief. This mechanism makes it effective for otalgia (ear pain) and related otologic conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Benzocaine Otic Solution

What is Benzocaine Otic Solution?

Benzocaine Otic Solution is a Local anesthetic drug developed by Lachlan Pharma Holdings, indicated for Otalgia (ear pain) / acute otitis media pain relief.

How does Benzocaine Otic Solution work?

Benzocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission in the ear.

What is Benzocaine Otic Solution used for?

Benzocaine Otic Solution is indicated for Otalgia (ear pain) / acute otitis media pain relief.

Who makes Benzocaine Otic Solution?

Benzocaine Otic Solution is developed by Lachlan Pharma Holdings (see full Lachlan Pharma Holdings pipeline at /company/lachlan-pharma-holdings).

What drug class is Benzocaine Otic Solution in?

Benzocaine Otic Solution belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Benzocaine Otic Solution in?

Benzocaine Otic Solution is in Phase 3.

What are the side effects of Benzocaine Otic Solution?

Common side effects of Benzocaine Otic Solution include Local irritation or burning sensation, Allergic contact dermatitis, Methemoglobinemia (rare, with excessive use).

What does Benzocaine Otic Solution target?

Benzocaine Otic Solution targets Voltage-gated sodium channels and is a Local anesthetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing